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C A N C E R
TET2 deficiency reprograms the germinal center B cell 
epigenome and silences genes linked 
to lymphomagenesis
Wojciech Rosikiewicz1,2*†, Xiaowen Chen1*, Pilar M. Dominguez3*‡, Hussein Ghamlouch4, 
Said Aoufouchi5, Olivier A. Bernard4, Ari Melnick3§, Sheng Li1,6,7,8§
The TET2 DNA hydroxymethyltransferase is frequently disrupted by somatic mutations in diffuse large B cell 
lymphomas (DLBCLs), a tumor that originates from germinal center (GC) B cells. Here, we show that TET2 defi-
ciency leads to DNA hypermethylation of regulatory elements in GC B cells, associated with silencing of the 
respective genes. This hypermethylation affects the binding of transcription factors including those involved 
in exit from the GC reaction and involves pathways such as B cell receptor, antigen presentation, CD40, and 
others. Normal GC B cells manifest a typical hypomethylation signature, which is caused by AID, the enzyme 
that mediates somatic hypermutation. However, AID-induced demethylation is markedly impaired in TET2- 
deficient GC B cells, suggesting that AID epigenetic effects are partially dependent on TET2. Last, we find that 
TET2 mutant DLBCLs also manifest the aberrant TET2-deficient GC DNA methylation signature, suggesting 
that this epigenetic pattern is maintained during and contributes to lymphomagenesis.
INTRODUCTION
Disruption of epigenetic programming has emerged as a hallmark 
of various types of hematological malignancies (1), including diffuse 
large B cell lymphomas (DLBCLs), which is the most common form 
of non-Hodgkin lymphomas (2). A number of studies have demon-
strated disruption of cytosine methylation [5-methylcytosine (5mC)] 
patterning as a factor linked to the clinical outcome and biology of 
DLBCL (3). One manner in which aberrant 5mC contributes to the 
growth of these tumors is through silencing of tumor suppressors 
such as CDKN2A, a process that is linked to unfavorable clinical 
outcome in DLBCL and other hematological cancers (4). The degree 
to which 5mC patterning in DLBCL deviates from that in normal 
B cells is negatively correlated with survival time (5). Moreover, 
DLBCLs manifest substantial inter- and intratumor epigenetic 
heterogeneity, which has been linked to poorer clinical outcomes, 
likely due to increased population fitness (6). The importance of 
aberrant 5mC in DLBCL is further supported by data suggesting 
favorable response of newly diagnosed, high-risk DLBCL patients 
to DNA methyltransferase inhibitors (DNMTi) given in combina-
tion with standard chemoimmunotherapy (7). Nevertheless, little is 
still known about the molecular mechanisms underlying aberrant 
5mC in lymphomagenesis. The fact that many patients with high-
risk DLBCL will die of their disease underlies the clinical impor-
tance of understanding the mechanisms through which cytosine 
methylation patterning is affected during lymphomagenesis.
5mC is well established as an epigenetic mark associated with 
transcriptional silencing, especially when linked to promoter- 
associated CpG islands (8). The distribution and dynamic turnover 
of cytosine methylation are controlled by enzymes that modify or 
excise cytosine residues in DNA. The ten-eleven translocation 
(TET) family enzymes are involved in active DNA demethylation, 
catalyzing the oxidation of 5mC to 5-hydroxymethylcytosine 
(5hmC), 5-formylcytosine, or 5-carboxylcytosine (9). More recently, 
it has been appreciated that 5hmC also functions as an epigenetic 
mark, and when linked to gene enhancers, is associated with activa-
tion of nearby genes (10, 11). Of the three TET-family genes, TET2 
is the one most often altered by somatic mutations in hematological 
malignancies, including in approximately 10% of patients with 
DLBCL (12–15). These mutations are similar to those observed in 
myeloid and T cell neoplasms and disrupt TET2 through various 
mechanisms, including accumulation of nonsense, missense, or 
frameshift mutations within the TET2 coding region, splicing sites, 
or other evolutionary conserved regions of the gene, which result in 
partial or total loss of function of the TET2 protein (16–18).
DLBCLs arise from B cells transiting the germinal center (GC) 
reaction. Programmed deletion of TET2 in hematopoietic cells or 
B cells disrupts the ability of GC B cells to undergo class switch 
recombination and terminal differentiation (14, 19, 20). Furthermore, 
GC-directed TET2 deletion in mice results in accelerated develop-
ment of DLBCLs, thus confirming its role as a bona fide B cell 
tumor suppressor (14). One notable consequence of TET2 loss of 
function in GC B cells is focal loss of 5hmC at enhancers linked to 
B cell differentiation (14). Since TET2 deficiency in GC B cells leads 
to loss of 5hmC, it is reasonable to assume that TET2 deficiency 
could be connected with a consequent gain of 5mC levels. However, 
the impact of TET2 loss of function directly on cytosine methylation 
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patterning in GC B cells is unknown. Using a 450 K DNA methyla-
tion microarray in a cohort of patients with DLBCL, Asmar et al. 
(12) observed evidence of relative hypermethylation in CpG-rich 
regions in TET2 mutant DLBCL cases, which raises the possibility 
that TET2 loss of function might alter the epigenome through this 
mechanism in GC B cells. Here, we investigated the impact of TET2 
deficiency on cytosine methylation patterning in GC B cells in mice, 
how this links to disruption of transcriptional regulation, and 
whether and how these observations can be extended to primary 
human DLBCLs to illustrate the manner in which TET2 deficiency 
contributes to the tumor phenotype.
RESULTS
TET2 deficiency leads to hypermethylation in GC B cells
Given that TET2 mediates DNA demethylation, we hypothesized 
that TET2 deficiency in GC B cells might result in aberrant hyper-
methylation. To test this, we performed enhanced reduced repre-
sentation bisulfite sequencing (ERRBS) on sorted naïve B (NB) cells 
(B220+GL7−FAS−DAPI−) and GC B cells (B220+GL7+FAS+DAPI−) 
from Vav-Cre/Tet2−/− (conditional knockout) and Vav-Cre/Tet2+/+ 
(control) mice. Principal components analysis and unsupervised 
hierarchal clustering yielded a clear separation of methylation 
profiles between Tet2−/−- and Tet2+/+-sorted mouse GC B cells 
(Fig. 1, A and B). In contrast, there was little difference between the 
DNA methylation profiles of Tet2−/− and Tet2+/+ NB cells (fig. S1, 
A and B). A supervised analysis of 5mC profiles revealed 10,730 
differentially methylated cytosines (DMCs) in Tet2−/− GC B cells, 
compared to only 2091 DMCs in control Tet2−/− NB cells (q value < 
0.01; methylation difference > 25%; table S1 and Fig. 1C). In Tet2−/− 
GC B cells, DMCs were distributed approximately uniformly across 
chromosomes (Fig. 1D), and a majority of these (9043 or 84.3%) 
were hypermethylated (Fig. 1E). Of the 9043 hypermethylated 
DMCs, 2126 (23.5%) were located within promoter regions [2 kb 
up- and downstream of the transcriptional starting sites (TSSs)], 
where they could potentially influence gene expression.
The epigenetic signature of GC B cells is reported to be, for the 
most part, hypomethylated relative to that of NB cells (21, 22). Since 
TET2 is linked to demethylation, we next asked whether TET2 loss 
of function would affect formation of this characteristic GC B cell 
epigenetic signature. We first examined DMCs in TET2 wild-type 
(WT) NBs and GC B cells and observed that, of the total of 
22,599 DMCs in the two types of cells, 93.6% were hypomethylated 
(Fig. 1F and table S1), in accordance with previous reports. Notably, when 
comparing Tet2−/− NBs to Tet2−/− GC B cells, we observed signifi-
cantly fewer hypomethylated DMCs in Tet2−/− GC B cells than we 
observed in GC B cells when comparing TET2 WT NBs and GC B 
cells (12,841 versus 21,150; 8309 fewer; Fisher’s exact test, P value ≈ 0; 
Fig. 1, F and G, and table S1), suggesting that hypomethylation of 
these sites might be dependent on TET2 demethylating activity. 
Tet2−/− mice failed to demethylate 13,881 of the ~21,150 DMCs 
that were hypomethylated in Tet2+/+ mice (Fig. 1H). Nonetheless, 
more than half of the DMCs hypomethylated in Tet2−/− mice were 
also hypomethylated in WT Tet2 mice (7269 of 12,841; Fig. 1H), 
suggesting that demethylation of these 7269 residues is independent 
of TET2. Together, these results are consistent with the notion 
that TET2 loss of function might disrupt the normal biology of 
GC B cells in part through disruption of cytosine methylation 
patterning.
Tet2 deficiency links to transcriptional repression via 
promoter hypermethylation and loss of enhancer 5hmC
TET2 was shown to play a role in gene activation by demethylation 
of enhancers (23). Tet2-deficient GC B cells manifest an aberrant 
transcriptional signature featuring widespread gene repression that 
is associated with loss of gene enhancer (but not promoter) 5hmC 
peaks (14). It is possible that aberrant 5mC hypermethylation might 
also be linked to these enhancer effects. Alternatively, Tet2 deficiency 
might result in aberrant promoter methylation that could repress 
genes in cooperation with enhancer loss of 5hmC. To address 
these questions, we performed an integrative analysis of ERRBS DNA 
methylation profiles, genome-wide 5hmC profiles [hydroxymethylated 
DNA immunoprecipitation sequencing (hMeDIP-seq)] (14), and 
expression profiles [RNA sequencing (RNA-seq)] (14), all obtained 
from Tet2−/− versus Tet2+/+ GC B cells. We organized this analysis 
based on functional annotation of the genome into promoters 
(TSS ± 2 kbp), exons, introns, putative enhancers (defined as intergenic 
or intronic H3K27ac peaks in splenic B cells, excluding promoters), 
intergenic regions, and regions losing 5hmC signal [hypo–DHMRs 
(differentially hydro xymethylated regions)] (Fig. 2A). Notably, 
the number of hyper- DMCs overlapping with hypo-DHMRs, equal 
to 562 CpGs, is 7.69 higher than expected by chance (hypergeometric 
test, P value ≈ 0), considering sites covered by both ERRBS and 
hMeDIP-Seq reads. Moreover, hyper-DMCs are also overrepre-
sented at putative enhancers [fold change (FC) = 3.51; hypergeo-
metric test, P value ≈ 0]. These results are visualized in the UpSet 
plot (24) in Fig. 2B, where the number of hyper-DMCs overlapping 
with each region (or intersection of regions; e.g., intergenic enhancer) 
was normalized to the number of hyper-DMC sites per 100 CpGs 
covered by at least 10 ERRBS reads. The number of hyper-DMCs 
and of reference CpGs covered in each region is additionally shown 
in table S2. Last, the number of hyper-DMCs overlapping with pro-
moter regions was significantly underrepresented (FC = 0.41; hyper-
geometric test, P value ≈ 0). These results support the notion that 
TET2 is primarily responsible for the control of enhancers and, to a 
lesser degree, for control of promoter activity. Nevertheless, despite 
the underrepresentation of TET2 loss-of-function–related hyper-
methylation in promoters, 23.5% of hyper-DMCs were located in 
these elements (2126 of 9043; table S2), highlighting their potential 
functional relevance.
As an orthogonal approach, we focused on the previously de-
fined 1977 differentially expressed genes in Tet2−/− versus Tet2+/+ 
GC B cells (14). We mapped putative enhancers to the nearest 
genes, within 100 kb of the TSS, which effectively narrowed down 
the analysis to a set of 584 differentially expressed genes with known 
intronic or intergenic enhancers (25) in B cells. Of these 584 genes, 
395 were down-regulated and 189 were up-regulated in Tet2−/− GC 
B cells (Table 1). These 584 genes were separated into four catego-
ries based on the presence or absence of promoter hyper-DMCs and 
enhancer hypo-DHMRs. Fifteen of these genes showed both hyper- 
DMCs in promoter regions and hypo-DHMRs in enhancer regions 
(Table 1). Of these 15 genes, 14 showed down-regulated expression 
in Tet2−/− GC B cells (down-regulated:up-regulated ratio = 14:1; 
Table 1), which is significantly higher than expected by chance [hyper-
geometric test, false discovery rate (FDR) = 0.0094; Fig. 2C]. The 
respective enhancer DHMRs and promoter DMCs are shown in 
Fig. 2 (D and E). For example, we show that Jarid2, a gene that is 
associated with Polycomb complex functions and that was affected 
by hypermethylation in its promoter region, combined with an 
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intergenic enhancer hypo-DHMR and two hypo-DHMRs overlapping 
with a cluster of putative intronic enhancers (Fig. 2F). Twenty-eight 
genes manifested promoter hyper-DMCs without enhancer loss 
of 5hmC, and 22 of these 28 genes were down-regulated (down- 
regulated:up-regulated ratio = 3.7:1; hypergeometric test, FDR = 0.0407; 
Table 1). One hundred and fifty-four genes manifested decreased 
levels of enhancer 5hmC without promoter hyper-DMCs, and these 
genes were biased toward repression (down-regulated:up-regulated 
ratio = 3:1; hypergeometric test, FDR = 0.0016; Table 1). Collectively, 
these data suggest that either impaired enhancer 5hmC or promoter 
5mC patterning could be associated with transcriptional repression. 
This effect was most consistent when both marks were perturbed, 
Fig. 1. Tet2 deficiency leads to hypermethylation in GC B cells and loss of hypomethylation during the NB-to-GCB transition. (A) Principal components analysis 
based on ERRBS data from three Tet2−/− and three Tet2+/+ GC B cell (GCBs) samples. (B) Hierarchal clustering based on ERRBS data from three Tet2−/− and three Tet2+/+ GCB 
samples. (C) Comparison of differential methylation events in NB cells and GCBs. (D) Differential methylation events per chromosome. (E) Row-normalized heatmap of the 
methylation levels of differential methylation events in GCBs (three Tet2−/− replicates and three Tet2+/+ replicates). (F) Differential methylation during transition of NB cells 
to GCBs in Tet2+/+ mice. Each dot on the scatter plot represents an individual CpG called as differentially methylated. Blue dots represent hypomethylation, and yellow 
represent hypermethylation. (G) Differential methylation during transition of NB cells to GCBs in Tet2−/− mice. Each dot on the scatter plot represents an individual CpG 
called as differentially methylated. Blue dots represent hypomethylation, and yellow represent hypermethylation. (H) Venn diagram of the overlap between hypomethylated 
DMCs in Tet2−/− and in Tet2+/+ mouse models.
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Fig. 2. Cooperation of 5hmC loss in enhancers and 5mC gain in promoters enhances gene silencing. (A) Genomic features within which hyper-DMC distribution was 
studied. They include promoters, exons, introns, enhancers (defined as H3K27ac peaks from WT GC B cells, excluding promoters), DHMRs losing 5hmC signal, and 
intergenic regions. (B) This panel depicts an UpSet intersection diagram, showing the total set size and overlaps between the 9043 hyper-DMCs and genomic elements 
including DHMRs, enhancers (defined as H3K27ac peaks, excluding promoters), exons, promoters, and intergenic and intronic regions. The shaded circles connected by 
solid black lines in the bottom show the intersecting combinations of genomic elements. This panel illustrates all feature combinations with at least one 
hyper-DMC. The number of hyper-DMCs overlapping in each region (or regions intersection, e.g., intergenic enhancer) was normalized, by the total number of CpGs covered 
by ERRBS reads in this region (or intersection of regions), and multiplied the value by 100. (C) Heatmap of the expression levels (row normalized) of 15 down-regulated 
genes with 5hmC loss in enhancers and 5mC gain in promoters. (D) Heatmap and signal distribution of the 5hmC enrichment at 24 DHMR regions overlapping with 
enhancer regions of the 15 genes for which expression was visualized in (C). (E) Heatmap of 5mC enrichment at 25 hyper-DMCs overlapping with the promoter regions of 
15 genes for which expression (row normalized) was visualized in (C). (F) Genome browser view of the example Jarid2 gene locus, visualizing 5hmC loss in two of its 
enhancers and 5mC gain in its promoter.
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which occurred, however, at only a subset of TET2-dependent 
genes. Strengthening the argument that promoter hypermethylation 
due to TET2 deficiency is linked to transcriptional repression, we 
first narrowed down the list of 930 genes with hypermethylated 
promoters to 755 genes expressed at a threshold of at least 20 reads 
per gene mapped in all samples. Next, we confirmed that a set of 
755 genes with hypermethylated promoters is significantly overlapping 
with a list of down-regulated genes in TET2-deficient GC B cells 
(n = 69 genes; hypergeometric test, P value = 0.0016; fig. S2, B and 
C). Our work identified significantly differentially expressed genes 
with absolute FC of >1.2 and FDR less than 0.05. We next per-
formed gene set enrichment analysis (GSEA) using the set of 
755 expressed genes with hypermethylated promoters in Tet2−/− 
versus Tet2+/+ GC B cells and observed the significant enrichment 
for repression of these genes in the absence of TET2 (FDR = 0.02; 
fig. S2A). Moreover, this analysis revealed a list of 141 leading-edge 
genes, the expression of which was negatively affected to the highest 
degree with promoter hypermethylation (table S3). Leading-edge 
genes are core genes that contribute to the gene set’s enrichment 
signal.
Tet2 loss of function is associated with the repression of key 
B cell pathway genes
The above data illustrate how promotor hypermethylation, as a 
result of aberrant promoter demethylation, is associated with tran-
scriptional repression in Tet2−/− GC B cells. To gain a sense of the 
biological functions that might be perturbed by promoter hyper-
methylation in TET2-deficient GC B cells, we next performed a 
hypergeometric gene pathway enrichment analysis of 930 genes 
with hyper-DMCs in their promoter regions. This procedure yielded 
highly significant enrichment for genes induced in centrocytes as 
they exit the GC reaction, CD40-induced genes, and genes involved 
in antigen presentation (Fig. 3A and table S4). This is consistent 
with the light zone expansion and differentiation blockade observed 
in immunized Tet2−/− mice (14). Mechanistically, genes repressed 
and hypermethylated in Tet2−/− mice include genes that are nor-
mally only transiently poised during the GC reaction and that 
become aberrantly repressed in patients with somatic mutations of 
related histone acetyltransferase encoding genes CREBBP and EP300, 
as well as de novo bivalent genes, i.e., genes that were repressed in 
GC B cells through promoter H3K27me3 bivalent domains, modi-
fied by the histone methyltransferase EZH2 (Fig. 3A). These CREBBP, 
EP300, and EZH2 target genes are similar to those linked to CD40 
signaling, GC exit, and antigen presentation (25, 26), suggesting that 
Tet2 might normally oppose EZH2 while enhancing the actions of 
CREBBP and EP300. Furthermore, taking together all of the hyper-
methylated genes linked to the seven gene sets shown in Fig. 3A 
(n = 163), we again observed significant enrichment for repression 
of these genes in Tet2−/− GC B cells (FDR = 1.7×10−4; Fig. 3B and 
table S5). Further examination of the leading edge of this GSEA 
analysis (Fig. 3C and table S5) yielded genes including Tapbp and 
H2-Q7. Tapbp encodes tapasin, which is a subunit of the antigen 
processing (TAP) complex, responsible for binding of TAP1 and 
major histocompatibility complex (MHC) class I molecules, and 
which is required for an efficient peptide-TAP interaction (27), as 
well as for quality control of human leukocyte antigen-G (HLA-G) 
molecules (28). H2-Q7 is an ortholog of the human leukocyte antigen-A 
(HLA-A) gene, which is one of the major types of MHC class I heavy 
chain molecules. Down-regulation of these two genes might poten-
tially destabilize MHC class I complexes, thus impairing signals re-
quired for GC exit and helping GC B cells to escape from immune 
recognition mechanisms.
TET2-deficient hypermethylated regions are enriched 
for binding by key transcription factors essential for  
B cell development
During the humoral immune response, phenotypic transitions of 
GC B cells in and out of the GC reaction are controlled by transcrip-
tion factors (TFs) with stage-specific functions. To determine 
whether the binding sites for these TFs might be affected by aberrant 
5mC patterning in Tet2−/− GC B cells, we performed a motif enrich-
ment analysis using 2126 hyper-DMCs (±50-bp flanking regions) 
within the promoters of the 930 genes shown to have methylated 
promoters in Tet2−/− versus Tet2+/+ GC B cells (Fig. 2B). This anal-
ysis showed that 47 different TFs and regulators were enriched by 
this analysis; a number of these 47 proteins are relevant to con-
trolling the GC reaction (q value < 10%; Fig. 4A and table S6). These 
include BATF (B-cell-activating transcription factor), which is 
a basic leucine zipper TF that activates expression of activation- 
induced cytidine deaminase (AID) through the recruitment of the 
TET2 and TET3 proteins (29); interferon regulatory factor 4 (IRF4), 
which is the master regulator of the GC exit program (30); and nucle-
ar factor B 1 (NF-B1) and NF-B2, which are downstream of the 
B cell–activating pathways induced by B cell receptor and CD40 (31). 
We also observed enrichment of PU.1:IRF8 hybrid sites; notably, PU.1 
has been shown to activate gene expression via recruitment of TET 
proteins in normal pro–B cells (29, 32). Other motifs for B cell TFs, 
of note, included c-MYC and MAX, FOXM1, RAR, E2A, PAX5, and 
MEF2C. Disruption of binding sites for any of these factors could 
lead to aberrant transcriptional states in Tet2−/− GC B cells.
In accordance with these binding-motif findings, previous stud-
ies measuring TF affinity to methylated versus unmethylated DNA 
elements using either DNA methylation–sensitive site selection 
in vitro or ChIP-seq (chromatin immunoprecipitation sequencing) 
coupled to methylome analysis suggest that the TFs MAX, c-MYC, 
IRF4, FOXM1, and MEF2C might be biased toward binding with 
unmethylated motifs (33–35). However, the actual extent of aberrant 
TF motif DNA methylation is likely not fully captured by the 
ERRBS method used in our studies, as it is designed to enrich for 
CpG-rich regions. Hence, we conducted a GSEA analysis for the 
target gene sets of the key TFs shown in Fig. 4A, using the gene ex-
pression profiles of Tet2−/− versus Tet2+/+ GC B cells. This analysis 
indeed showed significant down-regulation of the target genes of all 
13 TFs in Tet2−/− GC B cells (Fig. 4B and fig. S3). To gain insight 
into the biological functions of these target genes, we first identified 
Table 1. The number and ratio of down-DEGs and up-DEGs with 5hmC 
loss in enhancer or 5mC gain in promoter.  
5hmC loss in 
enhancer
5mC gain 
in 
promoter
Number of Ratio 
(down to 
up-DEGs)Down-DEGs
Up-DEGs
Yes Yes 14 1 14.0:1
No Yes 22 6 3.7:1
Yes No 116 38 3.0:1
No No 243 144 1.7:1
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the genes contained in the leading-edge of the GSEA analysis of the 
target genes of the 13 TFs shown in Fig. 4B, which yielded 1274 genes 
(Fig. 4C). Notably, as visualized in Fig. 4D, these 1274 genes are over-
lapped significantly with 34 previously identified hypermethylated 
leading-edge genes (hypergeometric test, P value ≈ 0), which, as 
demonstrated in Fig. 3, are enriched for pathways essential in the exit 
from the GC reaction. This gene overlap prompted us to check 
whether these 1274 leading-edge genes are enriched for the same gene 
signatures. Hypergeometric analysis of these genes again identified 
significant enrichment of key GC exit genes including genes up- 
regulated in centrocytes, genes induced by CD40 genes in lymphoma, 
and genes involved with antigen processing and presentation (Fig. 4E 
and table S7). This analysis also showed enrichment for genes re-
pressed due to loss of function of CREBBP or EP300, as well as de 
novo bivalent chromatin genes regulated by EZH2 in the GC re-
action (Fig. 4E). Collectively, the data suggest that aberrant cytosine 
methylation induced by Tet2 loss of function might disrupt expression 
of genes that are targets of TFs that play critical roles in GC exit, 
which, in turn, might contribute to the differentiation blockade 
observed in Tet2−/− GCs (14), which should be further validated 
experimentally. These hypothesis-generating analyses may be useful 
to guide functional studies exploring the manner in which these TFs 
might contribute to the TET2-deficient phenotype in GC B cells.
TET2-deficient GC B cells manifest an AID loss-of-function 
signature
Somatic hypermutation of immunoglobulin genes during the GC 
reaction is mediated by AID (Aicda gene), through cytosine deamination. 
Fig. 3. Hypermethylation affects key pathways in B cell biology. (A) Result of pathway enrichment analysis of the 930 genes with hyper-DMCs in their promoter 
regions. Plot shows minus log10 of the FDR scores for the enrichment of genes in seven functional categories important in GC or DLBCL biology. FDR scores were computed 
using hypergeometric test for these 930 genes. (B) GSEA enrichment plots in Vav-Cre/Tet2−/− versus Vav-Cre/Tet2+/+ GC B cells, against 163 genes with hyper-DMCs in their 
promoter regions, which were enriched for pathways listed in (A). (C) Row-normalized gene expression of 34 genes, which were identified as “leading-edge genes” in the 
GSEA analysis shown in (B). Yellow represents high expression, and green represents low expression. NES, normalized enrichment score; Down-DEGs, down-regulated 
genes; FL, follicular lymphoma. Star (*) indicates the value of FDR below 0.05.
Rosikiewicz et al., Sci. Adv. 2020; 6 : eaay5872     17 June 2020
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
7 of 15
The effects of AID are not limited to immunoglobulin loci, and 
there is extensive bystander mutagenesis throughout the accessible 
genome in GC B cells (36). The effect of AID on non-immunoglobulin 
sites is markedly underlined by the characteristic DNA hypomethyl-
ation signature observed in normal GC B cells, which is largely 
mediated by AID, as GC B cells from Aicda−/− mice fail to manifest 
this hypomethylation (21). Several lines of evidence suggest that 
TET enzymes cooperate with AID cytosine demethylation (37–40). 
Fig. 4. Hypermethylated regions are enriched for binding motives of key TFs in B cell biology. (A) Heatmap of the FDR scores of the motif enrichment analysis 
conducted using Homer for hyper-DMCs (±50 bp) located in promoter regions. Each TF name is accompanied by a logo sequence of the binding site. (B) Minus log10 of 
the FDR scores for enrichment of the target genes of 13 TFs, the binding sites of which were identified as hyper-methylated in Tet2−/− GC B cells. FDR scores were computed 
using GSEA, as described in Materials and Methods. Direction of the enrichment is biased toward Vav-Cre/Tet2+/+ GC B cells, when compared with Vav-Cre/Tet2−/− GC 
B cells (i.e., target genes are down-regulated in Tet2−/− GC B cells). (C) Normalized gene expression of the 1274 genes identified as leading-edge genes in at least 1 of 13 
significantly enriched gene sets shown in (B). (D) Overlap between the 1274 leading-edge genes and 34 hypermethylated leading-edge genes of seven gene signatures 
important in GC exit or B cell biology. (E) Minus log10 of the FDR scores for the enrichment of 10 gene sets important in B cell biology. FDR scores were computed using 
hypergeometric test for leading-edge genes presented in (C) and (D). Star (*) indicates the value of FDR below 0.05.
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These considerations prompted us to examine whether the aberrant 
hypermethylation observed in Tet2−/− GC B cells might, in part, 
reflect disruption of Aicda-mediated hypomethylation.
To explore this question, we compared and contrasted ERRBS 
methylation profiles obtained in Tet2−/− versus Aicda−/− GC B cells 
and NBs. We focused the analysis on CpGs with at least 10 ERRBS 
reads in all samples from both mouse models to ensure a quantita-
tively meaningful comparison. First, we identified 19,111 CpGs that 
normally become hypomethylated in GC B cells versus NBs (Fig. 5A). 
Next, we determined how many of these 19,111 CpGs failed to 
become hypomethylated in Aicda−/− or Tet2−/− GC B cells. In the 
case of Aicda−/− mice, there was failure to hypomethylate 16,048 CpGs 
(84%), and in the case of Tet2−/− mice, there was failure to hypo-
methylate 12,756 CpGs (66.7%; Fig. 5A). Notably, 12,002 of these 
Aicda-dependent CpGs were also Tet2-dependent, indicating a 
highly significant overlap between these factors (hypergeometric 
test, P value ≈ 0; Fig. 5B). The CpGs that failed to demethylate in 
Aicda−/− GC B cells were associated with 1238 gene promoters. GSEA 
analysis on this Aicda-associated promoter gene set in Tet2−/− GC 
B cells indicated a significant trend for these genes to be expressed 
at lower levels in Tet2−/− GC B cells (FDR = 0.037; Fig. 5C).
We examined the link between, on the one hand, Aicda−/− and 
Tet2−/− failure to demethylate and, on the other hand, gene expression, 
using a second approach. We first identified 4198 genes that were 
up-regulated during the NB to GC B cells transition (FDR < 0.05 
and FC ≥ 1.2; Fig. 5D). Next, we identified the genes from this list 
that were not induced in Aicda−/− (n = 1500) or Tet2−/− (n = 507) 
GC B cells, respectively (Fig. 5D). Notably, there was significant 
overlap (n = 360 genes) between these lists (hypergeometric test, 
P value ≈ 0; Fig. 5E). Moreover, GSEA using the set of genes that 
were not induced in Aicda−/− GC B cells revealed significant enrich-
ment among genes that were also relatively repressed in Tet2−/− GC 
B cells (FDR ≈ 0; Fig. 5F).
We then performed an integrative analysis of DNA methylation 
and gene expression patterns in Aicda−/− and Tet2−/− GC B cells by 
merging the lists of genes that failed to demethylate their promoters 
with genes that failed to up-regulate their expression in each mouse 
model, which yielded 3111 and 1949 genes in Aicda−/− and Tet2−/− 
GC B cells, respectively. As would be expected from the previous 
analyses, there was significant overlap between these two integrated 
gene sets (hypergeometric test, P value ≈ 0; Fig. 6A). Moreover, the 
Aicda−/− integrated gene set was enriched for down-regulation in 
Tet2−/− GC B cells (FDR ≈ 0; Fig. 6B). We then examined biological 
functions linked to either the Aicda−/− or Tet2−/− GC B cell–integrated 
gene sets. We identified a total of 187 gene sets significantly enriched 
in at least one phenotype and observed significant overlap between 
these two pathway lists (n = 130; hypergeometric test, P value ≈ 0; 
Fig. 6C and table S8). Among pathways enriched for down-regulation 
in both cases were antigen processing and presentation, PRDM1- 
repressed genes, and genes that were aberrantly silenced in CREBBP 
or EP300 loss-of-function DLBCLs in mice (Fig. 6D). However, 
repression of genes linked to CD40 signaling and NF-B, as well as 
of genes normally induced in centrocytes, were enriched only in 
Tet2−/− mice, which, together with the preceding data, suggests that 
these two genes have partially but not fully overlapping functions in 
the GC reaction.
Recent reports indicated that Tet2/Tet3 double knockout results 
in down-regulation of Aicda expression and a corresponding defect 
in Aicda-induced mutagenesis (19). However, here, in the setting of 
a Tet2 single knockout, Aicda expression was not significantly 
perturbed (FDR = 0.83; fig. S4A). Tet2/Tet3 double-knockout B cells 
were reported to show significantly reduced 5hmC at the Aicda 
enhancers. In contrast, with Tet2 single knockout, we see only small 
differences in 5hmC and also relatively little differential 5mC at Aicda 
enhancers (fig. S4B). Therefore, the notable failure to demethylate 
Aicda regulated CpGs in Tet2 single-knockout mice is more likely 
due to disruption of Aicda-mediated demethylation of these residues 
than to effects on Aicda expression itself.
Last, one of the key functions of AID is generation of C-to-U 
(Cytosine- to-Uracil) mutations during somatic hypermutation (41). 
Since Aicda expression is not affected by Tet2 deficiency in our mice 
model (fig. S4A), it was not clear whether these GC B cells would 
manifest impaired immunoglobulin somatic hypermutation. For 
this, we performed targeted sequencing of the immunoglobulin 
locus heavy-chain joining region 4 (JH4) and S variable regions, 
which are known AID mutagenesis targets (42, 43), from Vav-cre/
Tet2+/+ and Vav-cre/Tet2−/− GC B cells (B220+Fas+GL7+). We exam-
ined the percentage of clones per replicate, with at least one C-to-T 
(Cytosine-to-Thymine) (i.e., U) mutations at the WRC motif, which is 
the preferred site for AID-induced C-to-U deamination (44). This com-
parison did not yield a significant difference between Tet2 WT and 
Tet2-deficient cells (Wilcoxon rank sum test, P value = 0.24; table S9). 
There was also no significant difference in the frequency of clones 
with at least one C-to-T mutation (Mann-Whitney U test, P value = 
0.15; Fig. 6E). Last, an orthogonal analysis revealed no significant dif-
ference in the C-to-T allele frequency in the JH4 or S regions (Mann- 
Whitney U test P value = 0.09; fig. S4C). Together, these results suggest 
that TET2 loss of function does not negatively influence the process 
of somatic hypermutation and that the impact of Tet2 deficiency 
on Aicda in GC B cells is mostly restricted to DNA demethylation.
Tet2−/− 5mC signatures are reflected in human TET2 mutant 
DLBCL patients
We wondered whether the effects of Tet2 deficiency in mouse GC B cells 
on 5mC would carry through to primary human DLBCLs. Along 
these lines, using DNA methylation arrays, a previous study iden-
tified 578 hypermethylated DMCs present in TET2-mutated 
DLBCL primary samples and corresponding to 315 genes (12). To 
directly compare orthologous genes between these two species, we 
first removed from consideration any genes with promoters that 
were not covered by both platforms (methylation array in human 
and ERRBS in mouse). Together, 241 of 315 hypermethylated genes 
in human TET2MUT DLBCL and 614 of 930 hypermethylated genes 
in Tet2−/− GC B cells were considered for further analysis. Despite 
the cross-species comparison and the well-known heterogeneity 
among human DLBCLs (14), the overlap between the lists of hyper-
methylated genes in both species was still statistically significant 
(n = 18 genes; hypergeometric test, P value = 0.02). Moreover, the 
241 hypermethylated human genes were significantly aberrantly 
repressed in murine Tet2−/− GC B cells as shown by GSEA 
(NES = −1.54, FDR = 0.01; Fig. 7A). In addition, running GSEA in 
the opposite direction, that is, testing of 614 murine Tet2−/− hyper-
methylated genes in the expression data in human TET2 mutant 
versus WT DLBCLs, showed a trend toward negative regulation 
of the murine Tet2-deficient gene signature in human DLBCLs 
(NES = −1.12, FDR = 0.53; Fig. 7B). To further probe similarities 
between signatures directly downstream of Tet2 in mouse and 
in humans, we examined gene pathways linked to the sets of 
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hypermethylated genes in each species. Among hypermethylated 
genes in both human and mouse, we show enrichment of genes 
up-regulated in centrocytes, of de novo bivalent genes in GC B cells, 
and of terminally differentiated genes in GC B cells (Fig. 7C and 
table S10). Moreover, using GSEA, we additionally show that in 
both human and mouse, the expression of most of these gene signa-
tures was skewed toward down-regulation (Fig. 7C). Collectively, 
the data indicate that TET2 loss of function results in an aberrant 
cytosine methylation pattern in GC B cells, leading to a state of 
aberrant epigenetic programming and silencing of critical gene 
pathways that is maintained in primary human DLBCLs, suggesting 
that these epigenetic effects are selected by and contribute to the 
disease phenotype.
DISCUSSION
Among hematologic malignancy disease alleles, TET2 somatic 
mutations are unique in that they occur in tumors arising from 
multiple hematopoietic lineages (15). Although DLBCLs arise 
from mature GC B cells, they seem to inherit TET2 mutations from 
hematopoietic stem cells (HSCs), which can give rise to additional 
hematologic malignancies harboring the same TET2 allele (15, 45). 
Therefore, we chose to use the Vav-cre/Tet2−/− model here as the 
most likely to be physiologically relevant to human lymphomagenesis, 
although formal proof via mutational analysis on matched HSC and 
lymphoma samples is still pending. TET2 is normally required for 
GC B cells to exit the GC reaction and undergo plasma cell differen-
tiation (14). Although the pathways leading to TET2 activation in 
the GC are not yet defined, it is plausible that cytokines produced by 
T cells such as interleukin (IL)–2, IL-4, IL-10, and IL-21 (46, 47), 
which signal to GC B cells through JAK-STAT (Janus kinase–signal 
transducers and activators of transcription), induce JAK2-mediated 
TET2 phosphorylation, as has been recently described for stem 
cells in the bone marrow (48). TET2-deficient GC B cells cannot 
up-regulate the plasma cell master regulator PRDM1 due, at least 
in part, to reduction in 5hmC at its locus (14). Tet2−/− GC B cells 
feature disruption of many enhancers linked to GC exit signaling 
pathways, antigen presentation, and terminal differentiation genes. 
This role of Tet2 in GC B cells is conceptually similar to the func-
tions of the histone modifiers KMT2D, CREBBP, and EP300, which 
are also commonly affected by loss-of-function mutations in 
DLBCL and result in enhancer dysfunction (2). The TET2-regulated 
transcriptome overlaps substantially with that regulated by CREBBP, 
and mutation of these two factors is generally mutually exclusive 
(14). However, whereas the role of enhancer loss of function in 
lymphoma pathogenesis is well established (2), very little is known 
about how disruption of 5mC patterning might contribute to these 
diseases. Although aberrant 5mC distribution has been shown to 
Fig. 5. TET2-deficient GC B cells manifest AID loss-of-function signature. (A) Examination of 5mC accumulation during NB to GC B cell differentiation in TET2- and 
AID-deficient mouse models. CpGs (19,111) that are hypomethylated during normal NB to GC B cell differentiation in a WT mouse model were taken as a reference. 
(B) Venn diagram showing the overlap between CpGs that accumulate 5mC in Aicda−/− and in Tet2−/− NB to GC B cell differentiation. (C) GSEA enrichment analysis of 
1238 genes accumulating 5mC during Aicda−/− NB to GC B cell transition, in Tet2−/− versus Tet2+/+ GC B cells. (D) Examination of gene inactivation during NB to GC 
B cell differentiation in TET2- and AID-deficient mouse models. Genes (4198) up-regulated during normal NB to GC B cell differentiation in a WT mouse model were taken 
as a reference. (E) Venn diagram showing the overlap between genes that remain silenced during Aicda−/− and Tet2−/− NB to GC B cell differentiation. (F) Enrichment of 
the 1500 genes that remain silenced during Aicda−/− NB to GC B cells transition, in Tet2−/− versus Tet2+/+ GC B cells.
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occur in DLBCL, it is not clear whether this is an early/causal or late 
event inherent to transformed cells (49). Here, we show that Tet2 
loss of function in GC B cells leads to disruption in 5mC patterning 
largely associated with gene promoters, with down-regulation of 
the respective transcripts. This effect is at least partially retained in 
primary human TET2 mutant DLBCLs, thus providing evidence 
that aberrant 5mC patterning can be an early event disrupting key 
gene regulatory pathways during lymphomagenesis. Genes affected 
by aberrant DNA hypermethylation in Tet2−/− GC B cells are in-
volved in similar pathways as those repressed by loss of enhancer 
5hmC. The fact that genes with both loss of enhancer 5hmC and 
gain of promoter 5mC are particularly strongly affected is sugges-
tive of a dual mechanism of action of gene disruption by TET2 loss-
of-function alleles.
DNA hypermethylation can lead to gene silencing through a 
variety of mechanisms, including direct repression due to recruitment 
of methyl-binding repressor proteins or indirect repression by 
reducing the affinity of TFs such as MAX, c-MYC, IRF4, FOXM1, 
RelA, and MEF2C, for their DNA binding sites (33). Target genes 
for these factors were among those aberrantly methylated and re-
pressed in Tet2−/− GC B cells. DNA hypermethylation at TF binding 
sites could occur through loss of recruitment of TET2 to convert 
5mC to 5hmC. Along these lines, we observed the enrichment for 
the binding sites of PU.1, E2A, and BATF in hypermethylated 
regions, which is notable because these TFs have previously been 
linked with gene activation via recruitment of TET proteins in 
B cells (29, 32). PU.1 and E2A have been shown to physically interact 
with the TET2 and TET3 proteins, recruiting them to the enhancers, 
where they contribute to increasing chromatin accessibility (32). 
Similarly, over 81% of BATF peaks are colocalized with 5hmC in 
murine B cells, which is lost upon conditional Tet2 and Tet3 knockout 
(29). Loss of 5hmC in Tet2-deficient GC B cells might therefore lead 
to a relative decrease in chromatin accessibility and the inability of 
other downstream TFs to regulate gene expression, which is also 
consistent with our observation of DNA hypermethylation at these 
sites. Collectively, these considerations underscore the notion that 
precise regulation of gene expression in the humoral immune response 
requires cross-talk between DNA and histone modifications, both 
of which are severely disrupted in Tet2-deficient GC B cells.
GC B cells typically undergo extensive AID-dependent DNA 
hypomethylation (21). We show that this effect of AID is severely 
impaired in the absence of TET2, without impairment of AID 
Fig. 6. TET2- and AID-deficient cells are enriched for the same gene signatures. (A) Venn diagram showing the overlap between the integrated methylation- and 
expression-based aberrant gene signatures in Aicda−/− and Tet2−/− mouse models. (B) Enrichment of the aberrant Aicda−/− gene signature (3111 genes) in Tet2−/− versus 
Tet2+/+ GC B cells. Enrichment plot was generated using GSEA and shows down-regulation in Tet2−/− GC B cells. (C) Result of pathway enrichment analysis of the 3111 and 
1949 genes with aberrant Aicda−/− and Tet2−/− signatures, respectively. FDR scores were computed using hypergeometric test. (D) Heatmap shows the FDR score of eight 
selected gene signatures from (C). FDR scores were computed using hypergeometric test. (E) Per-clone C-to-T mutation frequency at WRC motif, where W = A or T 
and R = G or A. Mann-Whitney U test was computed between Tet2−/− and Tet2+/+ conditions, combining mutation frequency values from each replicate accordingly to 
condition type.
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mutability on WRC sequence motif at the immunoglobulin variable 
region, during somatic hypermutation. This effect could be due to 
loss of AID expression, which has been reported to occur with double 
knockout of Tet2 and Tet3 (19). However, we show that in mice 
with Tet2 knockout alone, there is no reduction in AID expression 
and relatively little perturbation of AID gene regulatory elements, 
Fig. 7. TET2 loss of function in human DLBCL manifest Tet2-deficient GC DMC and gene signature. (A) Enrichment of the aberrant human TET2MUT gene signature 
(241 genes with hyper-DMCs in their promoters) in mouse Tet2−/− versus Tet2+/+ GC B cells. (B) Enrichment of the aberrant mouse Tet2−/− gene signature (614 genes with 
hyper-DMCs in their promoters) in human TET2MUT versus TET2WT DLBCL. (C) First and third columns of the heatmap represent the results of pathway enrichment analysis 
of 614 mouse and 241 human genes with hyper-DMCs in their promoters, respectively. FDR scores for these results were computed using hypergeometric test. Second 
and fourth columns represent the results of pathway enrichment analysis of the same gene sets, using GSEA in mouse Tet2−/− versus Tet2+/+ GC B cells and human TET2MUT 
versus TET2WT DLBCL, respectively. NES scores of all pathways in mouse and human are biased toward Tet2−/−/TET2WT.
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suggesting that residual Tet3 can still maintain AID expression 
without Tet2. Therefore, loss of hypomethylated cytosines in 
Tet2−/− mice is more likely due to impairment of AID-mediated 
deamination, consistent with studies that suggest interdependence 
between TET2 and AID in DNA demethylation (37–40). Cortellino 
et al. (37) suggested that AID can deaminate modified cytosine 
residues, which are then repaired to unmodified cytosines through 
excision repair. Moreover, Guo et al. (38) reported that AID prefer-
entially mediates DNA demethylation of 5hmCs but not of 5mCs. 
This notion is challenged by studies emphasizing low levels of 
AID-mediated deamination of hydroxymethyl cytosines due to the 
size of the hydroxymethyl modification (50, 51). However, it might 
also be possible that AID first deaminates 5mC to thymidine, which 
is then oxidized by TET2 to 5-hydroxymethyluracil (40), which can 
be further excised by base excision repair machinery to unmethylated 
cytosine (52). Together, our data suggest that in the GC B cell 
context, Tet2 plays a critical role in AID-mediated deamination of 
methylated cytosines.
TET2 is the only highly recurrently mutated member in the TET 
family in lymphomas, with somatic mutations occurring in 6 to 
12% of DLBCL (12–15). Our data point to aberrant DNA hyper-
methylation as a contributor to the malignant phenotype of TET2 
mutant DLBCLs, since aberrant repression of genes affected in this 
way by loss of TET2 (e.g., antigen presentation genes or interferon 
pathway) is strongly linked to DLBCL pathogenesis (2). This 
warrants consideration of DNMTi for the treatment of TET2 mutant 
patients. DNMTi are showing promising activity in high-risk 
DLBCLs, and perhaps, mutation of TET2 could serve as a biomarker 
to select patients for such treatment (7). However, it is important 
to emphasize that DNMTi alone would not likely fully reverse the 
aberrant silencing of Tet2 target genes caused by loss of 5hmC. The 
concept of targeting different layers of the epigenome has recently 
been shown to be particularly effective in TET2 mutant patients 
with acute myeloid leukemias (53). An equivalent strategy in DLBCL 
could include the use of HDAC3-selective inhibitors to rescue the 
effect of loss of 5hmC at gene enhancers (14), together with DNMTi 
to rescue the effect of DNA hypermethylation at promoters, and to 
more fully restore the expression of aberrantly silenced genes and 
thus the result in greater therapeutic efficacy.
MATERIALS AND METHODS
Animal models
Vav-Cre/Tet2f /f mice were obtained as a gift from R. Levine, Memorial 
Sloan Kettering Cancer Center (54). Experiments with conditional 
knockout of Tet2 (Tet2−/−) were conducted according to Gustave 
Roussy institutional guidelines and were authorized by the Direc-
tion Départementale des Services Vétérinaires du Val de Marne, as 
described previously (14). Aicda−/− mice were a gift from T. Honjo 
(Kyoto University Graduate School of Medicine), as described ear-
lier (21). All mice were maintained according to the Weill Cornell 
Medicine Institutional Animal Care and Use Committee–approved 
protocol (ID no. 2011-0031) and guidelines of the Research Animal 
Resource Center of Weill Cornell Medicine.
DLBCL patient samples
Analysis of the influence of TET2 mutations in DLBCL on expression 
levels was conducted on the same samples, as described previously. 
Briefly, a cohort of 128 tumors from patients with pathologic diagnosis 
of DLBCL were interrogated by targeted sequencing, as described in 
García-Ramírez et al. (55). The TET2 mutations in patients with DLBCL 
for this cohort was published and obtained in (14). Affymetrix U133 
plus 2 gene expression microarrays were performed on 84 matched 
DLBCL tumors in previous work, which were stored in the Gene Ex-
pression Omnibus (GEO) database (accession number GSE10846) (56).
Analysis of the influence of TET2 mutations in DLBCL samples 
on methylation levels was conducted on the methylation array data 
from Asmar et al. (12), which is accessible from the GEO database 
(accession number GSE37362). Samples include 12 patients with 
TET2 mutations. Briefly, the diagnoses were based on standard 
histology and immunophenotyping according to the 2008 World 
Health Organization lymphoma classification. Samples comprising 
more than 50 and 80% tumor cells were selected for DNA and RNA 
extraction, respectively. Genomic DNA was isolated after proteinase 
K digestion using the Purescript DNA Isolation Kit (Gentra Systems). 
Research on all human subjects was approved by the respective 
institutional review boards.
Mouse B cell isolation
To induce GC formation, Vav-Cre/Tet2−/− and Aicda−/− mice, and 
their corresponding controls, were immunized with sheep red 
blood cells (1 × 108 cells per mouse) or NP-CGG ratio of 20 to 25 
(from Biosearch Technologies) in alum (1:1). Mice were euthanized 
at day 10 after immunization, spleens were dissected, and mono-
nuclear cells were purified using Histopaque gradient configuration 
(Sigma). Isolation of NB cells and GC B cells was conducted from cell 
suspensions enriched in B cells by positive selection with anti-B220 
magnetic microbeads (Miltenyi Biotech, Germany). B cells were 
separated into NB cell (B220+GL7−FAS−DAPI−) and GC B cell 
(B220+GL7+FAS+DAPI−) using a BD FACSAria II sorter, as described 
previously (14, 21).
Enhanced reduced representation bisulfite sequencing
Genomic DNA from GC B cells of Aicda−/− and Aicda+/+ mice was 
bisulfite-converted using the EZ DNA Methylation Kit (Zymo 
Research), as described previously in Dominguez et al. (21). Base-
pair–resolution DNA methylation analysis was performed in Aicda−/− 
mice (n = 6, three males and three females) and Aicda+/+ mice 
(n = 7, three males and four females) following the ERRBS protocol 
previously described (57). The same protocol was applied to ge-
nomic DNA from a total of 12 samples of NBs and GC B cells in 
Vav-Cre/Tet2−/− and Vav-Cre/Tet2+/+ mice, with three replicates 
for each condition. DMCs were identified on the basis of logistic 
regression test with the following thresholds: q value < 0.01; methyl-
ation percentage difference of at least 25% (calculateDiffMeth function 
in R package methylKit) (58). Specifically, the logistic regression 
test was used to compare the fraction of methylated cytosines across 
the test and the control groups. The 2 test was used to determine 
the methylation differences. Further, the sliding linear model method 
was used to correct the P values for multiple testing. In associating 
genes with hypermethylated CpGs (hyper-DMCs), we considered 
all genes with promoter regions containing hyper-DMC. Here, 
promoter regions are defined as up/down to a distance of 2 kb from 
the TSSs in the mm10 reference annotation.
Motif enrichment analysis
Identification of known TF binding sites overrepresented among 
DHMRs in Vav-Cre/Tet2−/− and Vav-Cre/Tet2+/+ samples was 
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conducted using “findMotifsGenome.pl” from Homer (59). More 
specifically, the analysis was conducted for hypo-DHMR regions, 
identified as described above, overlapping with promoter regions. 
Moreover, the analysis was also conducted for hypermethylated 
regions, defined as regions 50 bp upstream or downstream of hyper- 
DMCs located within promoter regions. Motif enrichment analysis 
for these hyper-DMCs was conducted with a background of all ref-
erence promoters from the gencode (vM3) reference annotation.
Accession numbers
Raw sequence data of Vav-Cre RNA-seq, ERRBS, and hMeDIP-seq 
from the experiments conducted in GC B cells are stored under 
accession number GSE111700. Sequence data from Vav-Cre RNA-seq 
and ERRBS NBs are stored under accession numbers GSE132595 
and GSE132596. Raw sequence data of Vav-Cre/Tet2−/− and Vav-Cre/
Tet2+/+ SHM (somatic hypermutation) analysis are stored under 
accession number GSE140086.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/25/eaay5872/DC1
View/request a protocol for this paper from Bio-protocol.
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